The potential release date for results from a phase 2 trial of Pyrilutamide, a hair loss treatment that combines Minoxidil, Finasteride and RU58841. It was agreed that the results are expected to be released in June 2022.
Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.
Using a combination of low-dose topical finasteride (0.025%) and 0.5% pyrilutamide for hair loss, with a focus on minimizing side effects. The user seeks experiences and results from others who have tried this combination.
The post discusses speeding up verteporfin trials for hair loss treatment. The original poster, involved in the trials, requests help in crowdsourcing doctor emails to spread awareness and gather more support for the trials.
The conversation discusses the progress of Clascoterone (Breezula) for hair loss treatment, noting that COVID-19 delayed female trials by three months but Phase III trials for males are proceeding with a Special Protocol Assessment filed with the FDA. Users express hope for Breezula as an alternative to existing treatments like finasteride and minoxidil, despite concerns about its potential high cost.
The conversation is about a user offering free unused Eucapil after switching to finasteride for hair loss treatment. The user did not use Eucapil and is willing to give it away locally or ship it if costs are covered.
The user has been using finasteride for 15 years but is noticing increased hair loss. They are considering increasing the finasteride dosage or switching to dutasteride but are concerned about side effects; they previously stopped using minoxidil due to heart palpitations.
The user experienced significant hair shedding in the second week of using pyrilutamide, more so than with finasteride and minoxidil, and reported a headache after the first application. They believe the treatment may be working but acknowledge it's too early to confirm results.
Transitioning from finasteride to Pyrilutamide as a treatment for hair loss, and the potential risks associated with taking such a drug. People have discussed the need to wait at least 6 months in order to assess results, and are willing to risk their health trying this new medication.
Users discuss finding reliable sources for RU58841, focusing on lab tests, batch consistency, and community reputation. Some mention using alternatives like pyrilutamide.
PP405 is discussed as a potential adjunct therapy for hair loss, with skepticism about its effectiveness and trial results. Users mention combining it with finasteride and minoxidil for better results, while others debate the root causes of hair loss and the limitations of current treatments.
The conversation discusses a user's 3.5-month experience using pyrilutamide and minoxidil for hair loss, with some perceived improvement in the temples but potential recent regression. Another user suggests that maintaining the current hairline, even without improvement, is positive.
The user experienced side effects like heart palpitations, chest tightness, and fatigue from using 5% minoxidil foam once daily. They are considering switching to a 2% concentration due to lingering symptoms like lightheadedness and brain fog.
Hair loss treatments, specifically Pyrilutamide and Minoxidil/Finasteride/RU58841. Participants discussed their experiences with them and the results they have seen so far.
The user has been using finasteride and minoxidil for hair loss but experienced worsening temple recession. They suspect they might be more sensitive to testosterone and are considering trying RU58841 or CB 03 01 as additional treatments.
User shared progress on hair regrowth after 4 months of Spironolactone and iron infusions for Androgenic Alopecia. They see some improvement but struggle with perception; others note significant improvement.
RU58841 is effective for long-term hair loss treatment, often used with finasteride or dutasteride for better results. Users report varying experiences with side effects and effectiveness, with some noting improvements and others experiencing shedding or needing to adjust dosages.
A user applied pyrilutamide for 6 months without hair regrowth and is considering stopping due to cost and lack of results. Another user suggests switching to finasteride, which is cheaper and has shown regrowth for them.
The user has been using finasteride for years with little regrowth and recently started using Cécred edge drops, which have significantly improved their scalp condition. Another user mentioned combining Cécred with derma stamping for better results.
A user experienced a dry, scaly scalp two weeks after microneedling with a dermapen at 1mm and applying Rogaine foam. They tried moisturizers and coconut oil without success and are seeking advice.
A user experienced severe side effects, including heart-related symptoms, after increasing their oral minoxidil dosage to 5 mg, leading them to stop the medication and seek medical advice. Many users advised against high doses of oral minoxidil, suggesting anxiety as a possible cause, and recommended consulting a doctor or switching to topical treatments.
The user experienced severe side effects from finasteride, including cognitive and sexual issues, despite its effectiveness for hair growth. They are considering switching to RU58841 and seek insights from others who have made a similar change.
Kintor's Pyrilutamide results for hair loss treatment will be released soon. The treatment may replace current treatments like finasteride and minoxidil without systemic side effects.
A user shared their 3-year progress using 1mg finasteride and 5% topical minoxidil twice daily, reporting significant hair regrowth and some side effects like bloating, seborrheic dermatitis, and water retention. The user is happy with the results, noting improvements in both the crown and hairline.
The user's experience with Pyrilutamide for hair loss treatment, including their belief that it has sparked improvements in combination with other treatments such as Minoxidil and Finasteride. Another user was also hoping to see results from using Pyrilutamide alone.
Finasteride may cause elevated liver enzymes, potentially leading to liver issues, though this is rare. Users should monitor liver function and consider topical alternatives if liver sensitivity occurs.
A user experienced severe sexual side effects and man boobs after 11 months of finasteride use, despite initial positive results for hair growth. They are discontinuing finasteride and caution others about potential risks, suggesting that side effects may be more common than reported.
PP405 is in phase 2 trials for hair loss, with discussions on its cost and effectiveness compared to minoxidil and finasteride. Users are skeptical about its efficacy and timeline, with hopes for market release by 2027.